Importance No retrospective cohort study has assessed the effectiveness of semaglutide at
doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg). Objective To …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Background The weight loss benefit of semaglutide in patients with diabetes is well-
documented, but its clinical utility in treating obesity among patients without diabetes is less …

Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease
associated with various health complications and increased mortality. Lifestyle modifications …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly
semaglutide among adults with overweight or obesity. Methods We searched multiple …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …